COVID-19 mRNA vaccines have been demonstrated to boost anti-tumor effects; these findings may pave the way for the development of a universal cancer vaccine.<\/p>\n
Research teams at the University of Florida<\/a> (FL, USA) and the University of Texas MD Anderson Cancer Center<\/a> (TX, USA) have identified a promising connection between the administration of COVID-19 mRNA vaccines and improved survival rates in cancer patients undergoing immunotherapy. Their analysis of over 1000 skin and lung cancer patient records, alongside supporting mouse model studies, has laid the groundwork for larger clinical trials and marked significant progress toward the development of a universal cancer vaccine.<\/p>\n Immunotherapies, such as immune checkpoint inhibitors<\/a> (ICIs), are widely used to treat cancers, including melanoma and non-small-cell lung cancer. However, they often prove ineffective at treating cancers in their advanced stages. This is primarily attributed to the cancer\u2019s ability to evade immune detection and the compromised immune systems of late-stage patients.<\/p>\n Shifting to a non-specific approach<\/p>\n Traditionally, cancer vaccine development has focused on creating vaccines that specifically target antigens expressed by cancer cells. However, in July of this year, co-senior author Elias Sayour\u2019s team at the University of Florida published results from a preclinical study<\/a> that reshaped the approach to cancer vaccine development. In this research, the team combined ICIs with an experimental non-specific mRNA vaccine, designed to boost overall immune activity rather than target a specific tumoral protein. This non-specific mRNA vaccine, when used in combination with ICIs, successfully elicited a powerful anti-tumor response in mice by \u2018waking up\u2019 their immune systems.<\/p>\n These findings prompted lead researcher of the current study Adam Grippin (University of Texas MD Anderson Cancer Center), a former member of Sayour\u2019s lab, to question whether the pre-existing COVID-19 mRNA vaccines could work in a similar way to the experimental non-specific vaccine.<\/p>\n COVID-19 mRNA vaccines in cancer treatment<\/p>\n To explore this idea, a research team led by Grippin analyzed data from over 1000 patients with late-stage non-small-cell lung cancer or melanoma, treated at MD Anderson between 2019 and 2023. The study compared 180 lung cancer patients and 43 melanoma patients who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy to larger control groups of cancer patients who did not receive the vaccine.<\/p>\n The team identified a significant link between receiving a COVID-19 mRNA vaccine within 100 days of initiating immunotherapy and improved survival outcomes. In the lung cancer patients studied, median survival nearly doubled, rising from 20.6 months to 37.3 months. Similarly, in melanoma patients, median survival increased from 26.7 months to a range of 30\u201340 months. Notably, some melanoma patients were still alive at the time of data collection, indicating that the vaccine\u2019s impact on survival may be even greater than initially reported.<\/p>\n Interestingly, administration of non-mRNA vaccines for conditions like pneumonia and influenza was not linked to an increase in survival.<\/p>\n The most dramatic improvements in longevity were observed in patients whose tumors were unlikely \u2013 based on a variety of factors \u2013 to exhibit a strong immune response. Mouse model experiments conducted by the team validated these findings, demonstrating that combining ICIs with an mRNA vaccine could transform unresponsive cancers into responsive ones, effectively halting tumor growth.<\/p>\n What are the next steps in the COVID-19 mRNA vaccine research?<\/p>\n This research, presented at the ESMO Annual Meeting<\/a> (17\u201321 October 2025; Berlin, Germany)<\/a>, comes at an interesting time, just a couple of months after USA Health Secretary Robert F. Kennedy Jr. withdrew US$500 million in funding for mRNA vaccines<\/a> being developed to combat respiratory viruses. The decision to cut funding contrasts sharply with this growing body of evidence supporting the versatility of mRNA vaccines.<\/p>\n